Apr 01, 2026
Radiopharmaceuticals are a cornerstone of precision medicine, enabling clinicians to visualize disease at the molecular level while simultaneously delivering targeted radionuclide therapy to tumors and other pathological tissues. Their dual diagnostic and therapeutic potential has positioned them as a transformativ...
Read More...
Dec 05, 2025
Glypican-3 (GPC3) has emerged as one of the most promising therapeutic targets in oncology, particularly in hepatocellular carcinoma and select solid tumors. As a cell surface heparan sulfate proteoglycan that is overexpressed in approximately 75% of hepatocellular carcinoma cases while remaining virtually absent i...
Read More...
Dec 21, 2022
Nuclear Medicine is an integral part of today’s healthcare delivery system and provides an immense benefit to patient care. Over the past four-five decades, there has been intense growth in the Nuclear Medicine Market owing to the development of various radionuclide and radio-labeled compounds and equipment. The ap...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper